Bristol-Myers Again Rebuffs Plavix Fraud Claims
Under fire from investors who insist they've sufficiently pled scienter, Bristol-Myers Squibb Co. is bolstering its bid to toss the suit that says it misled shareholders with the Plavix patent deal,...To view the full article, register now.
Already a subscriber? Click here to view full article